Nelonemdaz is under clinical development by GNT Pharma and currently in Phase I for Burns. According to GlobalData, Phase I drugs for Burns have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nelonemdaz’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nelonemdaz overview

Nelonemdaz (Neu2000) is under development for the treatment of acute ischemic stroke, traumatic brain injury, traumatic spinal cord injury, acute myocardial infarction (AMI) and burn injury, cerebral infarction. It is administered intravenously. It acts by targeting both NR2B-specific N-methyl-D-aspartate (NMDA) receptor and oxidative stress.

GNT Pharma overview

GNT Pharma (GNT Pharma Co) that manufactures botanical-based medicine, nutraceuticals, over-the-counter drugs, and veterinary medicine. The company is headquartered in Seongnam, Kyonggi-do, South Korea.

For a complete picture of Nelonemdaz’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.